Fas, Fas-Associated Death Domain-Like Interleukin 1β-Converting Enzyme-Like Inhibitory Protein, and Apoptotic Features of Elderly Acute Myeloid Leukemia Based on Response to Induction Chemotherapy
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
A study was performed to examine the clinical outcome of triple-combination induction chemotherapy in 26 elderly Korean acute myeloid leukemia (AML) patients and to investigate apoptotic responses during and after treatment to determine whether the responses can be used as prognostic markers. Patients who had Western blot or polymerase chain reaction analysis findings of higher expression levels of Fas-associated death domain-like interleukin 1β-converting enzyme-like inhibitory protein (FLIP) on day 7 after chemotherapy were more likely to have complete remission, but there was less or no correlation with Fas or a proapoptosis/apoptosis reaction. Expression of FLIP molecules may be, at least in part, an early prognostic indicator in the treatment of elderly AML patients.
- Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkable distinct response to standard chemotherapy-a Southwest Oncology Group study.Blood. 1997;89:3323–3329.
- Leith CP, Chen I, Kopecky KJ. Correlation of multidrug resistance (MDR1) protein expression with functional Dye/Drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant/MDR-/Efflux+ and MDR1+/Effluxcases.Blood. 1995;86:2329–2342.
- Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia.Leukemia. 1995;9:1491–1498.
- Schoch C, Haferlach T, Haase D, et al. Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognostic despite intensive treatment: a study of 90 patients.BrJ Haematol. 2001;112:118–126. CrossRef
- Hamblin TJ. The treatment of acute myeloid leukemia preceded by the myelodysplastic syndrome.Leukemia Res. 1992;16:4101–4108.
- Hoyle CF, de Bastos M, Wheatley K, et al. AML associated with previously cytotoxic therapy, MDS or myelo-proliferative disorders: results from the MRC’s 9th AML trial.Br J Haematol. 1989;72:45–53. CrossRef
- Nussler V, Saver H, Pelka-Fleischerf R, Holzel D, Wilmanns W. Clinical biochemical and cytotoxic parameters for distinguishing smouldering and rapidly proliferating variants of acute leukaemia.EurJ Hematol. 1990;45:19–25. CrossRef
- Howe RB, Bloomfield CD, McKenna RW. Hypocellular acute leukaemia.Am J Med. 1982;72:391–395. CrossRef
- Buchner T, Urbanitz D, Hiddenmann W, et al. Intensified induction and consolidation with or without maintenance chemotherapy for acute myeloid leukemia (AML): two multicenter studies of the German AML Cooperative Group.J Clin Oncol. 1985;3:1583–1589.
- Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.N Engl J Med. 1994;331:896–903. CrossRef
- Buchner T, Hiddemann W, Schaefer UW, et al. Combined effect of very early intensification and prolonged post-remission chemotherapy in patients with AML.Leukemia. 1992;6(suppl 4):68–70.
- Stone RM, Berg DT, George SL, et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine.Blood. 2001;98:548–553. CrossRef
- Stone RM, Berg TB, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia.N Engl J Med. 1995;332:1671–1677. CrossRef
- Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia.N Engl J Med. 1995;332:1678–1683. CrossRef
- Yates J, Glidewell O, Wiernik P, et al. Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study.Blood. 1982;60:454–462.
- Detourmignies L, Wattel E, Lai JL, Bauters F, Fenaux P. Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly?Ann Hematol. 1993;66:235–240. CrossRef
- Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first remission.J Clin Oncol. 2001;19:3244–3254.
- Mesters RM, Padro T, Bieker R, et al. Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia.Blood. 2001;98:241–243. CrossRef
- Schittenhelm M, Aichele O, Krober SM, Brummendorf T, Kanz L, Denzlinger C. Complete remission of third recurrence of acute myeloid leukemia after treatment with imatinib (STI-571).Leuk Lymphoma. 2003;44:1251–1253. CrossRef
- Dorr R, Karanes C, Spier C, et al. Phase I/II study of the p-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.J Clin Oncol. 2001;19:1589–1599.
- McSweeney PA, Niederwiesesr D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.Blood. 2001;97:3390–3400. CrossRef
- Bertz H, Potthoff K, Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia.J Clin Oncol. 2003;21:1480–1484. CrossRef
- Lowenberg B, Suciu S, Archimbaud E, et al. Mitoxantrone vs daunorubicin in induction-consolidation chemotherapy-the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukaemia in the elderly: final report. European Organization of the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.J Clin Oncol. 1998;16:872–881.
- Kim HJ, Whartenby KA, Georgantas RW, Wingard J, Civin CI. Human CD34+ cells are resistant to FasL due to high expression of FLIP.Stem Cells. 2002;20:174–182. CrossRef
- Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission induction chemotherapy in elderly patients of 65+ years with acute myeloid leukaemia: a randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukaemia Group.J Clin Oncol. 1989;7:1268–1274.
- Foon KA, Zighelboim J, Yale C, Gale RP. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukaemia.Blood. 1981;3:467–470.
- Godwin JE, Smith SE. Acute myeloid leukemia in the older patient.Crit Rev Oncol Hematol. 2003;48S:S17-S26. CrossRef
- Lewis NR, Pallis M, Russell NH. Fas receptor-Fas ligand system is independent of both CD34 status and chemosensitivity in acute myeloid leukemia.Exp Hematol. 2000;28:535–542. CrossRef
- Gupta P, Niehans GA, LeRoy SC, et al. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.Leukemia. 1999;13:44–53. CrossRef
- Komada Y, Sakurai M. Fas receptor (CD95)-mediated apoptosis in leukemic cells.Leuk Lymphoma. 1997;25:9–21.
- Braess J, Schneiderat P, Schoch C, Fiegl M, Lorenz I, Hiddemann W. Functional analysis of apoptosis induction in acute myeloid leukaemia-relevance of karyotype and clinical treatment response.BrJ Haematol. 2004;126:338–347. CrossRef
- Stahnke K, Eckhoff S, Mohr A, Meyer LH, Debatin KM. Apoptosis induction in peripheral leukemia cells by remission induction treatment in vivo: selective depletion and apoptosis in a CD34+ subpopulation of leukemia cells.Leukemia. 2003;17:2130–2139. CrossRef
- Fas, Fas-Associated Death Domain-Like Interleukin 1β-Converting Enzyme-Like Inhibitory Protein, and Apoptotic Features of Elderly Acute Myeloid Leukemia Based on Response to Induction Chemotherapy
International Journal of Hematology
Volume 82, Issue 4 , pp 327-332
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Induction chemotherapy
- Elderly AML patients
- Apoptotic responses
- FLIP molecule
- Industry Sectors
- Author Affiliations
- 1. Division of Hematology, Department of Internal Medicine, Catholic Hemopoietic Stem Cell Transplantation Center, Catholic University of Korea College of Medicine, 62, Youido-dong, Youngdungpo-ku, 150-713, Seoul, Korea